Optimizing Care for Patients With Tardive Dyskinesia

Release Date: February 12, 2025

Expiration Date: February 12, 2026

Activity Overview

A number of key domains (ie, social, physical, vocational, and psychological) relating to an individual’s life and function can be affected by tardive dyskinesia (TD), including social, physical, vocational, and psychological. Clinical recognition of the impacts of these domains is essential for clinicians to provide compassionate, patient-centered care, the initial part of which is a proper assessment, followed by selecting the best evidence-based therapy. Traditionally, no FDA-approved agents were available to treat TD, so using medications with a lower risk of TD and tapering medications at the first sign of TD symptoms was considered the best approach. However, the availability of vesicular monoamine transporter-2 (VMAT2) inhibitor therapy shifted the TD treatment paradigm. With this advance in therapy, clinicians whose scope of practice involves the care of patients with or at risk for TD require ongoing continuing education to hone and reinforce their clinical decision-making.

This educational activity is an archive of the live featured symposium held on January 17, 2025.

Target Audience

This educational activity is directed toward psychiatric nurse practitioners and psychiatric physician assistants. Advanced practice professionals on the front lines of care who treat psychiatric disorders in both outpatient and inpatient settings and other health care professionals interested in the treatment of psychiatric disorders are also invited to participate to further enhance knowledge of current psychiatric treatment options.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess clinical trial data for therapies for TD
• Incorporate therapies into individualized management plans for patients with TD